Affiliation:
1. Tokushima University / Medical Research, Tokushima, Japan; Japan Low Carbohydrate Diet Promotion Association, Kyoto, Japan
Abstract
Sodium-glucose Cotransporter-2 Inhibitors (SGLT2i) has been in focus for the pharmacotherapy of diabetes. SGLT2i contributes to decreasing blood pressure (BP) to some degree. BP changes were analyzed in 4 well-known mega-studies. They are Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients-Removing Excess Glucose (EMPA-REG OUTCOME) study, Canagliflozin cardioVascular Assessment Study (CANVAS), Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) and Dapagliflozin Effect on CardiovascuLAR Events (DECLARE)-TIMI 58. The ultimate goal of antihypertensive and hypoglycemic agents is not the achievement of target values, but the suppression of cardiovascular events. SGLT-2i show excellent strategy for event suppression and adjunct method for hypertension.
Publisher
Asploro Open Access Publications
Reference21 articles.
1. Association AD. 1. Improving Care and Promoting Health in Populations: Standards of Medical Care in Diabetes–2020. Diabetes Care. 2020 Jan;43(Suppl 1):S7-13. [PMID: 31862744]
2. Mauricio D, Alonso N, Gratacòs M. Chronic Diabetes Complications: The Need to Move beyond Classical Concepts. Trends Endocrinol Metab. 2020 Apr;31(4):287-95. [PMID: 32033865]
3. Atkins RC. Dr. Atkins’ New Carbohydrate Gram Counter. M. Evans and Company; 1996.
4. Bernstein RK. Dr. Bernstein’s Diabetes Solution. New York: Little, Brown and company; 1997.
5. Ebe K, Ebe Y, Yokota S, Matsumoto T, Hashimoto M, Sakai Y. Low Carbohydrate diet (LCD) treated for three cases as diabetic diet therapy. Kyoto Medical Association Journal. 2004;51:125-29.